IoM's Errant Committee
This article was originally published in RPM Report
Executive Summary
An Institute of Medicine committee offers its recommendations on addressing medication errors. Stakeholders are eager to embrace process improvements-but the committee is on a quest to encourage fundamental changes in the entire drug development enterprise.
You may also be interested in...
Drug Safety Reform: Did FDA Buy Time or Trouble?
FDA's senior management is worried that it may have created a political Frankenstein when it called for an outside review of the agency's role in drug safety decisions by the Institute of Medicine. The agency asked for the study to take the heat out of Congressional efforts to split up safety and efficacy reviews. The committee has shown interest in the arguments to create new publicly-funded centers for post-market trials.
Pediatric Disincentive? Implications Of US Pricing Bill
The ripple effects from the pending drug price reform legislation in the US would include fundamentally changing the math on the incentive to encourage pediatric research on new products.
Don’t Believe The Lack Of Hype: US Drug Price Reform Is Biggest Ever
The narrative about the Democrats’ march toward comprehensive drug pricing legislation in the US has emphasized what has dropped out of the original proposal. That obscures the bigger picture: it will be by far the most impactful drug pricing legislation ever enacted in the US.